Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $628000.0.

  • Pharma's Accounts Payables fell 1822.92% to $628000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $628000.0, marking a year-over-year decrease of 1822.92%. This contributed to the annual value of $883000.0 for FY2025, which is 1423.03% up from last year.
  • Pharma's Accounts Payables amounted to $628000.0 in Q3 2025, which was down 1822.92% from $933000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Accounts Payables ranged from a high of $1.6 million in Q3 2021 and a low of $530000.0 during Q1 2023
  • For the 5-year period, Pharma's Accounts Payables averaged around $1.0 million, with its median value being $919000.0 (2021).
  • The largest annual percentage gain for Pharma's Accounts Payables in the last 5 years was 6814.25% (2023), contrasted with its biggest fall of 6369.86% (2023).
  • Quarter analysis of 5 years shows Pharma's Accounts Payables stood at $919000.0 in 2021, then dropped by 3.16% to $890000.0 in 2022, then fell by 27.19% to $648000.0 in 2023, then increased by 28.86% to $835000.0 in 2024, then dropped by 24.79% to $628000.0 in 2025.
  • Its last three reported values are $628000.0 in Q3 2025, $933000.0 for Q2 2025, and $883000.0 during Q1 2025.